Related Experiment Video

Updated: Jun 26, 2026

Assessing Cellular Target Engagement by SHP2 (PTPN11) Phosphatase Inhibitors
08:45

Assessing Cellular Target Engagement by SHP2 (PTPN11) Phosphatase Inhibitors

Published on: July 17, 2020

Targeting group II PAKs in cancer and metastasis

Jeyanthy Eswaran1, Meera Soundararajan, Stefan Knapp

  • 1Structural Genomics Consortium, University of Oxford, Old road Campus, , Roosevelt Drive, Oxford, OX3 7DQ, UK. jeyanthy.eswaran@sgc.ox.ac.uk

Cancer Metastasis Reviews
|January 23, 2009
PubMed

Insights

p21 activated kinases (PAKs) are crucial in cell functions and cancer progression. Group II PAKs, distinct from Group I, offer unique opportunities for developing targeted cancer therapies and inhibitors.

Area of Science:

  • Molecular Biology
  • Cell Biology
  • Cancer Research

Background:

  • p21 activated kinases (PAKs) are vital regulators of cell motility, survival, angiogenesis, and mitosis.
  • PAKs are implicated in growth factor signaling, cytoskeletal reorganization, and cancer cell migration.
  • Overexpression of PAKs is linked to increased cancer migration, anchorage-independent growth, and metastasis.

Purpose of the Study:

  • To review recent advances in understanding the function of Group II PAKs in tumorigenesis and metastasis.
  • To explore opportunities for designing Group II PAK-specific inhibitors based on their unique catalytic domain dynamics.

Main Methods:

  • Review of recent scientific literature on Group II PAKs.
  • Analysis of high-resolution crystal structures of Group II PAKs.
  • Comparison of regulatory properties between Group I and Group II PAKs.

Main Results:

  • Group II PAKs (PAK4-6) exhibit distinct regulatory properties compared to Group I PAKs (PAK1-3).
  • High-resolution crystal structures are available for all Group II PAKs, facilitating rational drug design.
  • Group II PAKs play significant roles in cancer development and spread.

Conclusions:

  • Group II PAKs represent promising therapeutic targets for cancer treatment.
  • The unique catalytic domain dynamics of Group II PAKs offer novel strategies for inhibitor development.
  • Targeting Group II PAKs could lead to new anti-cancer drugs with improved specificity.

More Related Videos

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Metastasis02:30

Metastasis

Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...